ReviewClinics in liver disease2011
The global epidemiology of hepatocellular carcinoma: present and future.
Review in Clinics in liver disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 267 papers, 8 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
267 citing papers in PubMed, 8 syntheses or guidelines pooled it, 468 citations in OpenAlex.
- Aspirin in Patients with Viral Hepatitis: Systematic Review and Meta-Analysis of Observational Studies.Journal of gastrointestinal cancer · 2024Pooled it
- Clinical Practice Guidelines For the Management of Hepatocellular Carcinoma: A Systematic Review.Journal of gastrointestinal cancer · 2024Pooled it
- Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review.International journal of molecular sciences · 2022Pooled it
- The prognostic role of diabetes mellitus type 2 in the setting of hepatocellular carcinoma: a systematic review and meta-analysis.Croatian medical journal · 2022Pooled it
- Association between KIF1B rs17401966 genetic polymorphism and hepatocellular carcinoma susceptibility: an updated meta-analysis.BMC medical genetics · 2019Pooled it
- Multimodal Meta-Analysis of 1,494 Hepatocellular Carcinoma Samples Reveals Significant Impact of Consensus Driver Genes on Phenotypes.Clinical cancer research : an official journal of the American Association for Cancer Research · 2019Pooled it
- Blood glucose concentration and risk of liver cancer: systematic review and meta-analysis of prospective studies.Oncotarget · 2017Pooled it
- Oral Contraceptives Use and Liver Cancer Risk: A Dose-Response Meta-Analysis of Observational Studies.Medicine · 2015Pooled it
- Single-cell immune signature for detecting early-stage HCC and early assessing anti-PD-1 immunotherapy efficacy.Journal for immunotherapy of cancer · 2022Trial
- Efficacy and Safety Results from a Phase 2, Randomized, Double-Blind Study of Enzalutamide Versus Placebo in Advanced Hepatocellular Carcinoma.Clinical drug investigation · 2021Trial
- Association of 25-Hydroxyvitamin D with Liver Cancer Incidence and Chronic Liver Disease Mortality in Finnish Male Smokers of the ATBC Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2018Trial
- Hepatitis C virus testing for case identification in persons born during 1945-1965: Results from three randomized controlled trials.Hepatology (Baltimore, Md.) · 2018Trial
- Higher Glucose and Insulin Levels Are Associated with Risk of Liver Cancer and Chronic Liver Disease Mortality among Men without a History of Diabetes.Cancer prevention research (Philadelphia, Pa.) · 2016Trial
- Aflatoxin BJournal of fungi (Basel, Switzerland) · 2026Article
- Optimizing HCV Management Among Rohingya Refugees in Cox's Bazar, Bangladesh: Addressing Cofactors and Environmental Risks to Mitigate Long-Term Liver Disease Complications.Journal of immigrant and minority health · 2026Article
- Global, regional, and national burden of liver cancer due to hepatitis B, 1990-2021 and projections to 2051: a systematic analysis of the Global Burden of Disease Study 2021.European journal of gastroenterology & hepatology · 2026Article
- Epidemiological, clinical and therapeutic profile of hepatocellular carcinoma in Toamasina Madagascar.Ecancermedicalscience · 2026Article
- Elevated IL-17A level is associated with poor overall survival following immune checkpoint inhibitors combined with targeted therapy in hepatocellular carcinoma with hyperbilirubinemia.Frontiers in immunology · 2026Article
- The role of AP2M1 in oncofetal characteristics: integrative in silico, in vitro, and in vivo analyses using zebrafish models.European journal of medical research · 2025Article
- Article
207 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 2 institutions in 1 country.
Funding
Abstract
The global risk of hepatocellular carcinoma (HCC) has been largely driven by hepatitis B virus (HBV) infection for the past century, along with hepatitis C virus (HCV), aflatoxin, excessive alcohol consumption, and obesity/diabetes. The dominant effect of HBV on global HCC risk should decline as the population vaccinated against HBV grows older. Infection with HCV is also expected to decline. Projections of HCV-related HCC rates remaining high for another 30 years may be overly pessimistic. Alcohol may be less of a factor in HCC in coming years. However, obesity and diabetes may become even more important risk factors for HCC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.